Clinical trial
Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma
NCT00202930 · Jean M. Tersak, M.D., Other · Terminated
Key facts
| NCT number | NCT00202930 |
|---|---|
| Title | Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma |
| Official title | Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma |
| Lead sponsor | Jean M. Tersak, M.D., Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neuroblastoma, Opsoclonus-myoclonus |
| Intervention type | Drug |
| Interventions | anti-CD20 (Rituximab) |
| Enrollment | 4 |
| Start date | Jul 1, 2005 |
| Primary completion | Dec 1, 2008 |
| Completion | Feb 5, 2009 |
| First posted | Sep 20, 2005 |
| Last update posted | Jan 22, 2021 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: